189 related articles for article (PubMed ID: 21275408)
1. Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics.
Arias JL; Reddy LH; Othman M; Gillet B; Desmaële D; Zouhiri F; Dosio F; Gref R; Couvreur P
ACS Nano; 2011 Feb; 5(2):1513-21. PubMed ID: 21275408
[TBL] [Abstract][Full Text] [Related]
2. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor.
Reddy LH; Renoir JM; Marsaud V; Lepetre-Mouelhi S; Desmaële D; Couvreur P
Mol Pharm; 2009; 6(5):1526-35. PubMed ID: 19634915
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacy.
Maksimenko A; Alami M; Zouhiri F; Brion JD; Pruvost A; Mougin J; Hamze A; Boissenot T; Provot O; Desmaële D; Couvreur P
ACS Nano; 2014 Mar; 8(3):2018-32. PubMed ID: 24555414
[TBL] [Abstract][Full Text] [Related]
4. Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine.
Reddy LH; Marque PE; Dubernet C; Mouelhi SL; Desmaële D; Couvreur P
J Pharmacol Exp Ther; 2008 May; 325(2):484-90. PubMed ID: 18258784
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy.
Bui DT; Nicolas J; Maksimenko A; Desmaële D; Couvreur P
Chem Commun (Camb); 2014 May; 50(40):5336-8. PubMed ID: 24185552
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
7. A unique multidrug nanomedicine made of squalenoyl-gemcitabine and alkyl-lysophospholipid edelfosine.
Rodríguez-Nogales C; Sebastián V; Irusta S; Desmaële D; Couvreur P; Blanco-Prieto MJ
Eur J Pharm Biopharm; 2019 Nov; 144():165-173. PubMed ID: 31546021
[TBL] [Abstract][Full Text] [Related]
8. Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting.
Arias JL; Reddy LH; Couvreur P
Langmuir; 2008 Jul; 24(14):7512-9. PubMed ID: 18540685
[TBL] [Abstract][Full Text] [Related]
9. Polymer prodrug nanoparticles based on naturally occurring isoprenoid for anticancer therapy.
Trung Bui D; Maksimenko A; Desmaële D; Harrisson S; Vauthier C; Couvreur P; Nicolas J
Biomacromolecules; 2013 Aug; 14(8):2837-47. PubMed ID: 23829862
[TBL] [Abstract][Full Text] [Related]
10. Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells.
Sobot D; Mura S; Rouquette M; Vukosavljevic B; Cayre F; Buchy E; Pieters G; Garcia-Argote S; Windbergs M; Desmaële D; Couvreur P
Mol Ther; 2017 Jul; 25(7):1596-1605. PubMed ID: 28606375
[TBL] [Abstract][Full Text] [Related]
11. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.
Reddy LH; Dubernet C; Mouelhi SL; Marque PE; Desmaele D; Couvreur P
J Control Release; 2007 Dec; 124(1-2):20-7. PubMed ID: 17878060
[TBL] [Abstract][Full Text] [Related]
12. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.
Bildstein L; Pili B; Marsaud V; Wack S; Meneau F; Lepêtre-Mouelhi S; Desmaële D; Bourgaux C; Couvreur P; Dubernet C
Eur J Pharm Biopharm; 2011 Nov; 79(3):612-20. PubMed ID: 21784150
[TBL] [Abstract][Full Text] [Related]
13. Squalenoylation: a generic platform for nanoparticular drug delivery.
Desmaële D; Gref R; Couvreur P
J Control Release; 2012 Jul; 161(2):609-18. PubMed ID: 21840355
[TBL] [Abstract][Full Text] [Related]
14. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
15. Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery.
Sobot D; Mura S; Yesylevskyy SO; Dalbin L; Cayre F; Bort G; Mougin J; Desmaële D; Lepetre-Mouelhi S; Pieters G; Andreiuk B; Klymchenko AS; Paul JL; Ramseyer C; Couvreur P
Nat Commun; 2017 May; 8():15678. PubMed ID: 28555624
[TBL] [Abstract][Full Text] [Related]
16. Self-assembly of polyisoprenoyl gemcitabine conjugates: influence of supramolecular organization on their biological activity.
Lepeltier E; Bourgaux C; Maksimenko A; Meneau F; Rosilio V; Sliwinski E; Zouhiri F; Desmaële D; Couvreur P
Langmuir; 2014 Jun; 30(22):6348-57. PubMed ID: 24835925
[TBL] [Abstract][Full Text] [Related]
17. Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells.
Trabulo S; Aires A; Aicher A; Heeschen C; Cortajarena AL
Biochim Biophys Acta Gen Subj; 2017 Jun; 1861(6):1597-1605. PubMed ID: 28161480
[TBL] [Abstract][Full Text] [Related]
18. In vitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better.
Mura S; Buchy E; Askin G; Cayre F; Mougin J; Gouazou S; Sobot D; Valetti S; Stella B; Desmaele D; Couvreur P
Biochimie; 2016 Nov; 130():4-13. PubMed ID: 27519301
[TBL] [Abstract][Full Text] [Related]
19. Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor.
Valetti S; Maione F; Mura S; Stella B; Desmaële D; Noiray M; Vergnaud J; Vauthier C; Cattel L; Giraudo E; Couvreur P
J Control Release; 2014 Oct; 192():29-39. PubMed ID: 24984010
[TBL] [Abstract][Full Text] [Related]
20. Decoration of Squalenoyl-Gemcitabine Nanoparticles with Squalenyl-Hydroxybisphosphonate for the Treatment of Bone Tumors.
Rodríguez-Nogales C; Desmaële D; Sebastián V; Couvreur P; Blanco-Prieto MJ
ChemMedChem; 2021 Dec; 16(24):3730-3738. PubMed ID: 34581019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
